Penumbra, Inc. (PEN) Competitors & Peers
The 5 largest companies in the same industry as Penumbra, Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| ABT | Peer | $109.93 | P/E 41.0RSI 59Cap 191.5 B |
| SYK | Competitor | $325.87 | P/E 34.7RSI 61Cap 124.9 B |
| MDT | Competitor | $101.80 | P/E 25.0RSI 64Cap 130.2 B |
| BSX | Partner | $42.75 | P/E 18.0RSI 45Cap 63.5 B |
| EW | Peer | $102.14 | P/E 59.4RSI 77Cap 58.7 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- UROYPartner
Peninsula Energy operates the Lance project in Wyoming, USA, on which UROY holds 1% and 4% gross revenue royalties.
Model-inferred, unverified — treat as a lead, not evidence - BSXPartner
Penumbra entered into a definitive agreement to be acquired by Boston Scientific for approximately $14.5 billion.
Model-inferred, unverified — treat as a lead, not evidence - MCKSupplier
McKesson acts as a wholesale distributor of Penumbra's thrombectomy and neurovascular devices to hospital systems.
Model-inferred, unverified — treat as a lead, not evidence - CAHSupplier
Cardinal Health is a primary distributor of Penumbra's medical products to interventional radiology and stroke clinics.
Model-inferred, unverified — treat as a lead, not evidence - CORSupplier
Cencora (AmerisourceBergen) distributes Penumbra's neurovascular and peripheral thrombectomy devices to clinics and hospital pharmacies.
Model-inferred, unverified — treat as a lead, not evidence - MDTCompetitor
Penumbra and Medtronic compete directly in the neurovascular stroke treatment market, particularly in mechanical aspiration and stent retriever devices.
Model-inferred, unverified — treat as a lead, not evidence - SYKCompetitor
Stryker's Neurovascular/Vascular division competes directly with Penumbra in ischemic stroke aspiration catheters and neurovascular thrombectomy devices.
Model-inferred, unverified — treat as a lead, not evidence